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Abstract
When small molecules or proteins are injected into live animals, their physical and chemical properties will significantly
affect pharmacokinetics, tissue penetration, and the ultimate routes of metabolism and clearance. Fluorescence molecular
tomography (FMT) offers the ability to non-invasively image and quantify temporal changes in fluorescence throughout the
major organ systems of living animals, in a manner analogous to traditional approaches with radiolabeled agents. This
approach is best used with biotherapeutics (therapeutic antibodies, or other large proteins) or large-scaffold drug-delivery
vectors, that are minimally affected by low-level fluorophore conjugation. Application to small molecule drugs should take
into account the significant impact of fluorophore labeling on size and physicochemical properties, however, the presents
studies show that this technique is readily applied to small molecule agents developed for far-red (FR) or near infrared (NIR)
imaging. Quantification by non-invasive FMT correlated well with both fluorescence from tissue homogenates as well as
with planar (2D) fluorescence reflectance imaging of excised intact organs (r
2=0.996 and 0.969, respectively). Dynamic FMT
imaging (multiple times from 0 to 24 h) performed in live mice after the injection of four different FR/NIR-labeled agents,
including immunoglobulin, 20–50 nm nanoparticles, a large vascular imaging agent, and a small molecule integrin
antagonist, showed clear differences in the percentage of injected dose per gram of tissue (%ID/g) in liver, kidney, and
bladder signal. Nanoparticles and IgG1 favored liver over kidney signal, the small molecule integrin-binding agent favored
rapid kidney and bladder clearance, and the vascular agent, showed both liver and kidney clearance. Further assessment of
the volume of distribution of these agents by fluorescent volume added information regarding their biodistribution and
highlighted the relatively poor extravasation into tissue by IgG1. These studies demonstrate the ability of quantitative FMT
imaging of FR/NIR agents to non-invasively visualize and quantify the biodistribution of different agents over time.
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Introduction
Pharmacokinetic, biodistribution, and metabolic clearance char-
acteristics are important properties that can influence the overall
efficacy of novel therapeutics, imaging agents, and macromolecular
delivery vectors [1,2,3,4,5]. In order to achieve an effective level of
agent in the target tissues (i.e. sites of disease, inflammation, tissue
remodeling, tumor growth, or other biological changes) the agent
should extravasate from circulating blood to the tissue of interest or
site of action, either accumulating non-specifically, binding to a
molecular target, and/or undergoing cellular internalization. The
type of agent, dictated by physicochemical properties such as size,
charge, and chemical composition, will not only influence
pharmacokinetics and biodistribution but will also influence the
volume of distribution, the route of metabolism, and clearance. In
the development of both therapeutic agents and imaging agents, all
of these parameters contribute to the risk assessment of an agent
with regard to efficiency of targeting, assessment of off-target
accumulation, and prediction of potential sites of adverse reactions.
Preclinical biodistribution and pharmacokinetics data for
investigational agents are routinely obtained in animal studies
using radiolabeled materials [6]. Many of these studies employ
post-mortem scintillation counting of the labeled radioactivity in
excised organs and tissues [7,8]. Additional understanding of the
kinetic changes in biodistribution has generally required either the
sacrifice of multiple animals at multiple time points or the use of
non-invasive nuclear imaging techniques. PET and SPECT
imaging can provide 3-dimensional spatial distribution datasets
of radio-labeled imaging agents or therapeutics. By combining
these imaging approaches with CT, which provides additional
anatomical context, the quantitative accuracy of the PET and
SPECT data can be improved [9]. However, widespread use of
PET or SPECT for biodistribution studies can be limited by cost,
the restricted availability of the radionuclide-labeled agents, and
the extra precautions and safety guidelines required for working
with radioactivity. As an alternative, some researchers have
examined near infrared fluorescent imaging as a convenient, easy,
and rapid means of assessing agent biodistribution in excised organ
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[7,10,11]. In support of that early work, we present the FMT as a
robust and sensitive instrument enabling detection, visualization,
and quantification of fluorescence distributed throughout the body
of living mice [12,13,14,15,16,17,18,19] in a manner analogous to
PET imaging.The natural extension of this FMT technology to full-
body biodistribution measurements may offer an approach to
augment whole body PET and SPECT approaches. An additional
benefit of the use of fluorescence for biodistribution studies is the
unique ability to simultaneously distinguish multiple agents after IV
injection. Spectrally resolved optical imaging offers the opportunity
to track up to four separate agents, each labeled with a different
fluorophore that emits at a different wavelength. Upon simulta-
neous injection of two labeled agents, the relative biodistributions of
two labeled agents could be directly and quantitatively compared.
In these studies, we built upon recent advances in optical
tomographic imaging and FR/NIR agents to demonstrate the
utility of non-invasive FMT to detect, localize, and quantify agent
biodistribution in the major organ systems. For this, we used
empirical testing with a variety of FR/NIR-labeled agents to
establish 3D regions of interest (ROI) that optimally capture
differentorganswith minimaloverlap.BSA-VT680XLFMTresults
agreed well with comprehensive ex vivo assessments of organs, both
by 2D organ imaging as well as by quantification of fluorescence
within tissue homogenates. Subsequent dynamic FMT imaging
(multiple time points from 0 to 24 h) was performed using four
different types of FR/NIR-labeled imaging agents, including a
1.4 kDa drug-like integrin antagonist [20], a 250,000 kDa vascular
agent [21,22], 20–50 nm fluorescent nanoparticles [23], and
fluorophore-labeled proteins (BSA and IgG1). Careful, quantitative
interpretation of temporal imaging datasets, taking into account the
signal contributed by circulating agent, yielded useful information
regarding the amount and time course of agent extravasation and
localization into specific tissues. These imaging agents showed
differences in liver, kidney, and bladder accumulation, with the
nanoparticles and IgG1 favoring liver/kidney signal, the small
molecule agent showing expected rapid kidney and bladder
clearance, and the high molecular weight vascular agent showing
both liver and kidney clearance. Additional assessment of the
fluorescence volumes quantified within the animals provided a
simple indication of the volume of distribution differences, with the
integrin agent showing much greater dissemination into tissues than
larger agents, despite its very short blood half-life, and immuno-
globulin showing expected poor extravasation into tissue.
FMT biodistribution assessment, by virtue of its safety and ease
of use, may be ideal for the routine study of small molecule
imaging agents or larger therapeutic biomolecules (antibodies or
proteins minimally affected by fluorophore labeling). Future
combination of FMT with CT imaging or fluorescent contrast
agents, to provide anatomical co-registration, may further advance
the robustness of biodistribution imaging.
Results
Control studies to establish tomographic imaging
analysis regions for different organ systems
To quantitate fluorescence biodistribution in the different
organs of living mice, and changes over time, studies were
designed as depicted in Figure 1 using intravenous injection of
fluorescent agents. For initial optimization of biodistribution
analysis procedures, however, normal nude, or depilated conven-
tional mouse strains, received injections of specific imaging agents
Figure 1. Diagrammatic representation of the FMT biodistribution model. Mice are injected with NIR-labeled agents at time 0 and imaged
by FMT immediately, at the time when all of the signal would be attributed to the vasculature. At regular times thereafter, mice are reimaged to
assess the dynamic changes in tissue distribution, including kinetics of extravasation into specific organ regions as well as the kinetics of tissue
clearance.
doi:10.1371/journal.pone.0020594.g001
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Tomographic imaging provided 3-dimensional fluorescence data-
sets to accompany the photographic image acquired of each
mouse’s body. A 264 grid was overlaid on the mouse image (from
neck to tailbase) as a consistent frame of reference for analysis. A
gastric emptying imaging agent, administered orally, was used to
define the stomach region upon immediate tomographic imaging
(left panel), and this agent emptied into the intestines (right panel)
within 3 hours (Fig. 2A). The region of interest (ROI) for the
stomach was placed just above and to the right of the mouse
midline/centerline intersection and captured an area in the ventral
third of the mouse, whereas the intestinal region was captured by a
large cylindrical ROI in the abdominal region as depicted.
Intravenous free fluorophore (VivoTag680XL) defined both the
bladder and the brain region, specifically signal associated with
blood vessels within the brain, when imaged within 15 minutes
after injection (Fig. 2B). VivoTag680XL-labeled bovine serum
albumin (BSA-VT680XL) accumulated in the liver at 24 h after
IV injection, allowing the identification of the majority of the liver
region (Fig. 2C). The ROI was purposely designed to capture
approximately 70% of the liver to avoid overlap with the
gastrointestinal tract and lung regions. Injection of a vascular
agent, imaged immediately after injection, highlighted the heart
and carotid/jugular vessels (Fig. 2D). A lysosomal cathepsin-
activatable agent [16] detected eosinophil-related cathepsin
activity in the lungs of asthmatic BALB/c mice after IV injection,
helping to define the major regions of the lungs (Fig. 2E). The
intravenous renin imaging agent was activated by normal levels of
renin activity in the kidneys of C57BL/6 mice (Fig. 2F).
In the case of stomach, bladder, kidney, and heart imaging, the
ROIs placed to define these organs were deliberately sized larger
than the actual organs to provide sufficient room for mouse-to-
mouse variability. Liver, intestine, and lung ROIs were sized as a
compromise to achieve maximal specific organ capture and
minimize overlap with other organ systems. The composite ROI
model for FMT imaging of organ tissue biodistribution is
represented in Figure 3. ROI placement for skin fluorescence
assessment (not shown) was performed by placing a cylinder ROI
consistently on the upper right torso to capture the outer voxel
layer of fluorescence, with the grams of tissue calculated based on
the volume of the ROI.
Validating terminal in vivo distribution patterns of
labeled bovine serum albumin (BSA) by FMT and ex vivo
FRI tissue imaging
Three mice per group were administered an IV injection of
2 nmol of BSA-VT680XL and imaged non-invasively by
FMT2500 at 24 h to reconstruct 3-dimensional fluorescence
images (Fig. 4A, left panel). Whole-body animal imaging and
image reconstruction were quick, approximately 12–15 minutes,
respectively. As IV albumin would be expected to accumulate
Figure 2. Establishing FMT image analysis techniques for accurate assessment of specific organ systems. Nude or BALB/c mice received
administration of a variety of NIR fluorescence imaging agents to help to define specific organ regions and the appropriate placement of regions of
interest, ROI, for quantification. A, GastroSense 680 was orally gavaged, and mice were imaged immediately to visualize the stomach and to place a
3-dimensional ROI (see front and side views). At 2 h post-gavage, the agent emptied from the stomach and moved into the intestines, allowing clear
3D intestinal ROI placement. B, Free fluorophore (VivoTag 680XL) was injected IV, revealing very rapid appearance in the bladder (left panels) and
circulation through the vessels of the brain (right panels). C, BSA, known as a protein that predominantly localizes to the liver, was labeled with a NIR
fluorophore (VivoTag 680XL) and injected IV to define the liver region. D, The large NIR vascular agent, AngioSense 680, was injected IV to provide
signal defining the heart and carotid/jugular veins. E, Asthma-like inflammation was induced by immunization of BALB/c mice as previously described
[16], and ProSense 680 was used to image the pulmonary eosinophilia cathepsin activity, thus defining the lung regions in 3D. F, IV ReninSense 680
was activated by normal kidney renin activity, providing signal defining the kidney regions. The resulting 3D ROIs for each of these organ/tissue
regions defined the regions to be analyzed in subsequent whole body biodistribution studies, with a 2X4 grid providing a reference for proper ROI
placement. Fluorescence outside of each tissue region’s ROI is omitted for clarity.
doi:10.1371/journal.pone.0020594.g002
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approach to establishing a validated imaging system. As a control
for normal chow-related fluorescence, untreated mice with no
agent injection were also imaged (Fig. 4A, right panel). Organ
specific ROIs were established to capture 3-dimensional anatom-
ical regions corresponding to the heart, lungs, liver kidneys,
stomach, and intestines. A separate non-invasive imaging scan of
the head (not shown) captured brain fluorescence signal.
Quantitative analysis of each of these regions were adjusted by
taking into account the extent of any ROI overlaps. For example,
the heart signal was subtracted from the lung region, part of the
stomach signal was subtracted from the liver region, etc. FMT
quantification, represented as the % of the injected dose per gram
of tissue (%ID/g) was determined (Fig. 4B) using weights of organs
collected at study termination. Appropriate adjustments were
made to liver and lung weights to account for the ROI partial
capture of these tissues. The liver showed the highest intensity of
fluorescence per gram of tissue, followed by kidneys, lungs, heart,
and brain. All of the detected stomach and intestine signal could
be attributed to chow-related fluorescence, based upon similarity
to the signal seen in non-injected control mice.
Fluorescent-labeled BSA FMT results agreed well with
comprehensive ex vivo assessments of organs, both by FRI organ
imaging as well as by quantification of fluorescence within tissue
homogenates. FRI images of the post-mortem tissues (Fig. 4C)
clearly show dominant liver signal, with some signal seen in lungs,
kidneys, and heart. The level of fluorescence in the stomach and
intestines for the injected mice was similar to that seen in control
mice (data not shown), and the mean organ signal intensities
shown in Figure 3D agree well with the fluorescent signal
quantified by FMT in living mice. Figure 5A further shows that
FMT results correlate well with FRI, although it is no surprise that
the consensus of multiple studies suggests that FRI tissue imaging
underestimates signal in thicker or denser tissues such as brain,
heart, and kidneys. Organs from a representative mouse were also
homogenized and assayed for fluorescence levels by serial dilution,
yielding a very high correlation and excellent linearity to non-
invasive FMT imaging (Fig. 5B). These results also show not only
that the results correlate but that the FMT %ID/g values are also
in very close agreement to the independent ex vivo homogenate
measurements.
Assessing temporal in vivo whole body tissue distribution
of a variety of different Fluorescent-labeled agents
Dynamic FMT imaging (multiple time points from 0 to 24 h)
was performed using four different FR- or NIR-labeled agents,
including IgG1 (150 kDa), fluorescent nanoparticles (20–50 nm
diameter), a vascular imaging agent (250 kDa), and an integrin
antagonist (1.4 kDa). These agents differ widely in molecular
weight and chemical composition and would be expected also to
differ in pharmacokinetics, tissue distribution, tissue clearance
kinetics, and routes of metabolism. Careful, quantitative interpre-
tation of temporal imaging datasets, taking into account the signal
contributed by circulating agent, is an important consideration
when determining the amount and time course of agent
extravasation and accumulation in specific organ tissues, as
illustrated in Figure 1. Whole body imaging of living mice
receiving these agents (Fig. 6A) showed the changes over time in
total signal (i.e. signal from both tissue and blood), showing three
patterns of dynamic changes over time for the four agents. Little
information could be obtained from this data alone with regard to
the kinetics of extravasation of these agents into the tissue.
However, comparison to the typical plasma pharmacokinetic
profiles for these agents (Fig. 6B), normalized to %ID (and then
corrected for initial loss of agent to the bladder), shows that the
rate of decline of signal in the plasma was much more rapid than
seen in the whole body imaging, suggesting that each of these
agents was distributing to the tissue to some degree. By imaging
immediately after agent injection, we were able to normalize the
starting time point FMT quantification and the plasma levels. By
subtracting the normalized plasma PK data from the whole body
imaging results (Fig. 6C), quantification of the tissue distribution
dynamic profile was achieved. Each of the four agents used in this
study showed distinct profiles of tissue distribution. Most notably,
the small molecule integrin imaging agent cleared rapidly from the
blood and achieved ,30% of the injected dose in the tissue at 1 h.
In the absence of high plasma levels to drive tissue accumulation,
this agent started clearing from the tissue immediately thereafter
with a tissue half-life of approximately 20 h. The vascular and
nanoparticle agents, despite sharing very similar plasma pharma-
cokinetics, differed in their tissue distribution kinetics, with the
vascular agent showing peak tissue signal (,60%ID) at 5 h and a
tissue half-life of ,40 h and the nanoparticles showing substan-
tially lower peak tissue accumulation (,35%ID) but with a very
long residence time (tissue t1/2.100 h). IgG1 showed the slowest
Figure 3. Organ region model for biodistribution study
analysis. The ROIs defined in Fig. 2 using a variety of imaging agents
helped to generate an analysis model that was applied to all
biodistribution studies. Specific ROIs were designed to optimally
capture most of each organ region while minimally capturing nearby
organs. In the case of unavoidable overlap, i.e. heart/lung, bladder/
intestines, and stomach/liver, careful calculations were made to
subtract overlapping signal.
doi:10.1371/journal.pone.0020594.g003
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life .100 h.
Assessing dynamic in vivo organ distribution patterns of
a variety of different fluorescent-labeled agents
Further analysis of whole body imaging datasets for the four
agents represented in Figure 6 yielded temporal information on
liver, lung, kidney, heart, bladder, and skin signal (Fig. 7). Again,
the imaging data acquired by FMT captured signal originating
from both the organ tissue and the blood within the vessels of the
organs. This assessment alone was somewhat misleading, partic-
ularly when examining very early time points at which agent levels
were high in the circulation. A similar approach to the whole body
tissue assessment shown in Figure 6 (i.e. subtraction of normalized
Figure 4. Validation of FMT biodistribution imaging techniques using NIR-labeled BSA. Nu/nu mice (n=3 per group) received either BSA-
VT680XL or no injection (Control), and mice were noninvasively imaged by FMT2500 at 24 h post-injection, a time when the agent would no longer
be in circulation but would be at maximal levels in the tissue. Organ ROIs defined in Figs. 2 and 3 were applied for proper quantification of
fluorescence, and the data was normalized to % injected dose per gram of tissue (assessed at study termination). Organ weights were adjusted
appropriately for liver and lungs to account for incomplete capture of the full organs, based on prior studies (not shown). A, Tomographic images of
injected and control mice revealing BSA-VT680XL distribution (left panel) and normal chow-related fluorescence in the controls (right panel). Brain
fluorescence was collected in separate FMT image acquisitions (not shown). B, Quantification of fluorescence in injected and control mice, revealing
predominant liver distribution of labeled BSA, with control mice data suggesting that all of the stomach and intestine signal could be attributed to
chow-related fluorescence. C, Collection of specific organs was performed as an independent verification of the fluorescence quantified non-
invasively by FMT. D, Fluorescence intensity patterns seen for the different organs, although not objectively quantitative due to the 2D acquisition,
were similar to those seen by FMT imaging.
doi:10.1371/journal.pone.0020594.g004
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again making the assumption that at time zero all of the signal
can be attributed to the blood. The plasma PK values were
normalized for each organ and subtracted from each organ’s total
%ID/g value (essentially ‘‘zeroing’’ each organ for the initial
imaging time point). The resulting plasma corrected tissue levels
gave a clear picture of the kinetics of extravasation of each agent
into each organ tissue. Bladder signal was not corrected be-
cause we have found minimal vascular contribution to bladder
fluorescence.
The integrin antagonist showed very early bladder signal due to
its low molecular weight and rapid kidney clearance (Fig. 7A), with
very low signal (i.e. less than 5–6%ID/g) seen in other tissues. The
vascular and nanoparticle agents (Fig. 7B&D) also show a very
early bladder signal spike upon imaging, attributed to a small
percentage of trapped free fluorophore that shows as 10–12%ID at
the starting time point with rapid disappearance. The overall
profiles of these two agents in other tissues were similar, but they
showed differences in liver and heart signal. In contrast, IgG1
signal was dominated by liver accumulation as well as long term
general accumulation in most tissues (Fig. 7C) that was highly
variable. There was negligible signal in the bladder region,
revealing that bladder vasculature generally contributes only
minimally to the overall signal in the bladder, even at peak levels
in circulation.
Further analysis of liver:kidney ratios (Fig. 8) provided a relative
understanding of the metabolic fate of each of the agents. Again,
the corrected %ID/g values presented a picture of early kidney
clearance of vascular, nanoparticle, and integrin antagonist agents.
For the vascular and nanoparticle agents, this appeared to be due
to the rapid clearance of fluorophore and agent metabolites at
early time points and agreed with the kinetics of bladder signal in
the animals. At later times, the vascular agent showed evidence of
both liver and kidney roles in clearance. In the case of the integrin
antagonist, the kidneys appeared to be the major route of
clearance, accounting for the high bladder signal and relatively
poor plasma pharmacokinetic profile. In contrast, the nanoparticle
agent and IgG1 both showed a predominant liver signal, a pattern
of distribution expected for these agents.
Fluorescence volume assessment as an indicator of
volume of distribution
By standard pharmaceutical calculations, the volume of
distribution (also known as the ‘‘apparent volume of distribution’’),
is the theoretical volume of fluid into which an administered drug
would have to be diluted to produce the resulting plasma drug
levels. Although volume of distribution has no absolute physio-
logical meaning (i.e. does not provide actual physiologic volumes),
it has been a useful pharmacokinetic parameter to predict the
extent of distribution into bodily water or body fat. FMT
quantification of fluorescence volume (mm
3) in living mice would,
in theory, provide a more direct surrogate for volume of
distribution calculations, and results for four fluorescent agents
are shown in Figure 9. As fluorescent agents passively extravasate
into tissue, it would be expected that their concentrations would
decrease, while their volumes would increase. At early time points,
we expected an overestimation of fluorescent volumes due to the
‘‘partial volume effects’’ seen when analyzing fluorescent signal (i.e.
the increase in apparent voxel numbers when signal occurs on the
interface between multiple voxels in 3 dimensions). This effect
would be expected to be particularly strong when applied to
imaging tissue as fine and widespread as the vascular system, and it
is interesting to note that all four agents showed approximately
7000–8000 mm
3 of total fluorescence volume at time zero, the
time at which all fluorescence would be presumed to be in the
vasculature. Assuming that a 25 g mouse has approximately
2m m
3 of blood, this starting fluorescence volume corresponds to
an approximate 4-fold overestimate of blood volume.
Figure 5. Non-invasive FMT correlation to post-mortem tissue fluorescence. Quantitative FMT imaging data from three mice injected with
BSA-VT680XL was compared to post-mortem tissue assessment of organ fluorescence. A, Comparison of FMT quantitation to FRI gross tissue imaging
results, represented in mean intensity units of counts/energy, was performed. B, As a second approach to validation, an independent comparison to
quantitative fluorescence was performed from homogenized and diluted tissue samples, assayed in comparison to a VivoTag680XL standard curve.
For this second approach, the %ID/g was calculated from quantified fluorescence and weighed organ tissue. Both comparisons yielded excellent
correlation to FMT imaging, and tissue homogenate data also generated good agreement between absolute values of %ID/g.
doi:10.1371/journal.pone.0020594.g005
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(,0% increase), with the loss of plasma signal balanced by liver
tissue accumulation (Fig. 9). The relatively high tissue signal in the
absence of dramatic increases in fluorescence volume shows that
IgG1 extravasates to some degree but poorly penetrates into tissue,
as expected for immunoglobulin [24]. The nanoparticle fluores-
cence volume increased ,40% with half of this volume due to very
low concentration fluorescence. The vascular agent showed a
somewhat lower volume profile compared to the nanoparticle, and
75% of the volume was due to the lowest levels of fluorescence. As
expected because of its low molecular weight, the integrin
antagonist showed the greatest change, increasing in fluorescence
volume by 60% at 100 h, roughly. Adjusting for partial volume
effects, approximations of 100 h fluorescent volumes can be made
for the integrin, vascular, nanoparticle and IgG1 agents (8.0, 4.6,
6.2, and 2.0 mm
3, respectively) and compared to approximate
standard measures for vascular volume (,2m m
3), total body
water (,18 mm
3), and total body fat (,4m m
3) in a 25 g mouse
[25].
Discussion
Non-invasive preclinical imaging techniques are quickly be-
coming important tools in biomedical research, leading to
significant advances in the ability to monitor disease progression
and the impact of therapeutic intervention in a variety of disease
areas. With the recent advances in NIR tomographic imaging
technology we have been able to demonstrate the capabilities of
fluorescence molecular tomographic imaging to detect and
quantify fluorescent biomarkers of disease in sites of cancer,
inflammation, and infectious disease [16,17,26,27,28].
Recent studies by Nahrendorf et al. [30] have further advanced
the level of validation of FMT imaging by performing hybrid
PET-FMT imaging studies, using targeted agents labeled both
with a NIR fluorophore and
18Fo r
64Cu. The seamless integration
of tomographic FMT and PET datasets showed excellent spatial
co-registration and quantitative correlation, supporting the utility
of FMT imaging as a non-radioactive surrogate for PET imaging
in preclinical studies. To further take advantage of the robustness
of FMT imaging, and the use of fluorescence rather than
radioactivity, the present studies support the expansion of the
horizons of preclinical FMT imaging into quantitative biodistribu-
tion assessment. FMT imaging of fluorescent agents of vastly
different characteristics, from small molecule to large proteins to
nanoparticles, yielded quantitative time course information
regarding differential kinetics, organ distributions, and clearance
routes. By incorporating parallel blood pharmacokinetic data into
the imaging analysis, we were further able to separately quantify
the vascular signal and the extravasated tissue signal. This analysis,
although not the standard for PET biodistribution studies (which
does not remove the blood contribution), provided useful
information regarding the rate of extravasation into tissues and
was particularly helpful in understanding biodistribution patterns
at very early time points at which agents remained high in
Figure 6. Comparison of the kinetics of whole body fluorescence changes for four different NIR-labeled agents. Four different agents
were injected IV into nu/nu mice (n=3 mice/group), and animals were imaged immediately and at 1, 3, 6, 12, 24, and 100h post injection by
FMT2500. A, Whole body fluorescence was quantified at each time point using ROIs to capture the torso and head. Data was normalized as the
percentage of the injected dose. B, Plasma pharmacokinetics data was collected in separate sets of animals (as described in the Materials and
Methods) to provide data regarding circulating agent kinetics. Data was normalized as the percentage of the injected dose. C, An approximation of
the kinetics of agent accumulation in tissue was established by subtracting the normalized plasma pharmacokinetic profiles from the whole body
fluorescence profiles, making the assumption for each agent that the earliest imaging time point represented 100% of the agent in circulation.
Corrected results reveal differences in extravasation and whole-body tissue clearance rates for all four agents.
doi:10.1371/journal.pone.0020594.g006
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fluorescence was also critical in the proper interpretation of
biodistribution results in some instances; without PK correction,
skin, heart, and lung distribution were often grossly overestimated
due to the relatively high contribution of the circulating signal to
the overall imaging results. Additional techniques are being
explored that may allow the selective analysis of vascular and
tissue signal without the need for parallel pharmacokinetic studies,
further streamlining the biodistribution imaging process. Other
readouts, such as liver:kidney ratios and fluorescence volume of
distribution will need extensive validation to establish their utility
as robust readouts.
The major utility of FMT technology in biodistribution imaging
is likely to be the application to the design and modification of
antibodies or large protein therapeutics, as well as to the
characterization of novel optical imaging agents of any size. Such
an approach, in many instances, could be an option when rapid
biodistribution screening is needed. Fluorescence-based tomo-
graphic imaging by FMT uses no radioactivity, minimally affects
performance of large proteins, and presents an easy and user-
friendly option with no need for special safety considerations or
animal quarantine. Fluorescence approaches, however, may be
less useful than PET or SPECT imaging in the study of very low
molecular weight drug biodistribution, due to the significant
Figure 7. Comparison of the kinetics of organ biodistribution for four different NIR-labeled agents. Mice from the study in Fig. 6 were
further assessed for kinetic changes in fluorescence patterns in the different organ systems using techniques described in Figs 2 and 3. The plasma
level adjusted quantification of the kinetics of agent accumulation in each organ region was established by subtracting the normalized plasma
pharmacokinetic profiles from each organ’s fluorescence profile, making the assumption for each agent that the earliest imaging time point
represented 100% of the agent in circulation within that organ. Corrected results for A, the integrin antagonist, B, the vascular agent, C, IgG1, and D,
nanoparticles, reveal differences in the kinetics of extravasation into each organ and kinetic clearance patterns for all four agents.
doi:10.1371/journal.pone.0020594.g007
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you double or triple a drug’s size by fluorophore conjugation.
Although disease site fluorescence has been approached carefully
in many published studies, little work has been done to provide the
full picture of agent accumulation in non-target tissues other than
comparisons to specific control sites. With the current capabilities of
FMT imaging, we are now examining agent targeting to sites of
disease in the context of general biodistribution, helping in the
overall understanding of both the disease biology and specificity of
agent deposition. Further addition of kinetic readouts can be added
to understand rates of agent depositionto specific sites (in the case of
imaging time points post agent injection) and to track the
progression of disease (when imaging at different times following
initiationofdisease).Multi-channelcapabilityforFMTimagingalso
allows the simultaneous imaging of multiple agents, further
decreasing the need for large cohorts of animals.
In conclusion, we have demonstrated the ability of the FMT
imaging to non-invasively visualize and quantify whole-body tissue
biodistribution in a robust and consistent manner. The consistency
of the quantitative tomography, as well as its excellent correlation
with ex vivo assessment of organ tissue signal, provides a powerful
tool for quantifying the distribution and metabolic fate of FR- and
NIR-labeled agents. FMT imaging in antibody and imaging agent
research, utilizing NIR fluorescent labels, will provide a useful,
non-invasive tool for understanding their distribution and
metabolism.
Materials and Methods
Ethics statement
All experiments were performed in accordance with the
r e c o m m e n d a t i o n si nt h eG u i d ef o rt h eC a r ea n dU s eo fL a b o r a t o r y
Animals of the National Institutes of Health. The protocol (#01-
0904) was approved by PerkinElmer’s (In Vivo Imaging Division)
IACUC guidelines for animal care and use. No invasive or surgical
procedures were used in these studies, but all imaging activities were
performed under appropriate anesthesia to minimize animal distress.
Experimental animals
For whole body biodistribution studies, specific pathogen-free
female Nu/Nu mice (4–6 weeks of age) were obtained from
Figure 9. Determining relative fluorescence volume of distri-
bution changes of different imaging agents. Fluorescence data
from the study in Fig. 6 was further analyzed for kinetic changes in the
volume of fluorescence at different concentrations within the body as
determined by FMT2500. Fluorescence volume changes for four
different concentration ranges were represented in graphical form as
normalizations to starting volumes.
doi:10.1371/journal.pone.0020594.g009
Figure 8. Determining kinetic changes in liver:kidney ratios.
Mice from the study in Figs. 6 and 7 were further assessed for kinetic
changes in the ratios of liver to kidney signal as a way of classifying
each agent by its dominant route of tissue clearance. Plasma-corrected
fluorescence signal in the liver and kidney (i.e. signal in the tissue only)
was used to determine plasma PK corrected liver:kidney ratios.
doi:10.1371/journal.pone.0020594.g008
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environment (72uF; 12:12-h light-dark cycle) under specific-
pathogen free conditions with water and food provided ad libitum.
For PK studies, specific pathogen-free female CD-1 mice (6–8
weeks of age) were obtained from the same vendor and kept under
the same conditions as above.
Fluorescent agents
Commercially available (PerkinElmer Inc., Boston, MA) near
infrared imaging agents and custom conjugates were used to optimize
and perform biodistribution studies (summarized in Table 1). All
agents, except for GastroSense 750 were dosed at 2 nmol/mouse
intravenously. GastroSense 750 (0.25 nmol/mouse PO), is a
gastrointestinal imaging agent, AngioSenseH680 is a vascular imaging
agent; ProSenseH680 detects regions of increased lysosomal cathepsin
activity; ReninSense 680 FAST is activated by kidney renin;
IntegriSenseH 750 accumulates in regions of avb3 integrin upregula-
tion; AngioSPARKH 750is a nanoparticle-based vascular imaging
agent; VivoTagH 680XL (VT680XL) is a FR/NIR fluorophore.
Custom protein-fluorophore conjugates were produced using
bovine serum albumin (BSA) that was purchased from Sigma-
Aldrich (ST. Louis, MO), and murine IgG1 purchased from
Rockland (Gilbertsville, PA) to provide reference agents for
biodistribution studies. N-hydroxysuccinimide (NHS)-ester label-
ing of proteins was performed using the 680 nm fluorophore
(VivoTag 680XL, PerkinElmer). Briefly, the NHS ester moieties of
VivoTag 680XL (pH 7 for 1 h at room temperature) reacted with
primary amino groups of proteins to form stable amide bonds. In
this manner, a small number of lysine residues (generally 1 to 5) in
antibodies and other proteins can be labeled with fluorophore,
with free fluorophore removed by size exclusion chromatography.
Conjugation ratios were easily assessed by measuring absorbance
of the conjugates at 280 and 680 nm with appropriate extinction
coefficients to determine protein and fluorophore concentration,
respectively. Labeling for both BSA (BSA-VT680XL) and IgG1
(IgG1-VT680XL) achieved ,3 fluorophores per protein molecule,
and these conjugates were dosed in animals at 2 nmoles of
fluorophore/mouse IV. These conjugates showed excellent
stability when stored at 4C and, upon in vivo injection, showed
no evidence of release of free fluorophore.
In vivo biodistribution imaging
Nu/Nu mice were injected IV with 2 nmoles of FR/NIR
fluorescent agents and imaged at time 0, 1, 3, 6, and 24 h
following injection. At the time of imaging, mice were anesthetized
by inhalation in a chamber containing a mixture of isoflorane and
oxygen then imaged using the FMT 2500 fluorescence molecular
tomography in vivo imaging system (PerkinElmer Inc., Boston,
MA). For whole body imaging, the anesthetized mice were placed
in the supine position, centrally in the imaging cassette, to capture
the whole body (excluding the head) of the animal within the
imaging scan field of the imaging system. For imaging the head,
the mice were placed in the prone position in the imaging cassette
for a separate scan. After positioning the mouse, the imaging
cassette was adjusted to the proper depth to gently restrain the
mouse and then inserted into the heated docking system (regulated
at ,37uC) in the FMT imaging chamber. A FR/NIR laser diode
transilluminated (i.e. passed light through the body of the animal to
be collected on the opposite side) the animal body, with signal
detection occurring via a thermoelectrically cooled CCD camera
placed on the opposite side of the imaged animal. Appropriate
optical filters allowed the collection of both fluorescence and
excitation datasets, and the multiple source-detector fluorescence
projections were normalized to the paired collection of laser
excitation data. The entire image acquisition sequence took
approximately ,8–10 min (torso) and ,2–3 min (head) per
mouse.
FMT reconstruction and analysis
The collected fluorescence data was reconstructed by FMT
2500 system software (TrueQuant, PerkinElmer Inc., Boston, MA)
which compensates for the effects of tissue heterogeneity on light
scattering [29], allowing for the quantification of fluorescence
signal within multiple organ regions. Three-dimensional regions of
interest (ROI) were drawn to encompass lung, heart, liver,
stomach, kidney, intestine, and bladder tissue regions. For
visualization and analysis purposes, FMT 2500 system software
provided 3D images and tomographic slices. The total amount of
fluorescence (in pmoles) in different organ sites was automatically
calculated relative to internal standards generated with known
concentrations of appropriate FR/NIR dyes. To prevent loss of
low-level fluorescence following dissemination of agents into
tissues, no thresholding of fluorescence datasets was applied. The
percent injected dose (%ID) at each time point was determined
relative to the initial imaging time point for each animal, assuming
that combining whole torso and head scan at the start captured
100% of the pmols injected IV. In some studies in which only the
full torso scan was collected, the starting quantification was defined
Table 1. Characteristics of Fluorescent-Labeled Agents.
Agent Description
Fluorophore per
molecule
Peak
Ex/Em Approximate Size Imaging Utility
VivoTag-680XL Fluorophore 1 668/688 1860 g/mol Labeling of proteins
BSA-VT680XL Bovine Serum Albumin 3 668/688 72,000 g/mol Liver contrast agent
IgG1-VT680XL Control IgG1 3 668/688 160,000 g/mol Control for specific IgG1
ProSense 680 Cathepsin-Activatable Multiple quenched 680/700 400,000 g/mol Detection of disease-related proteases
ReninSense 680 FAST Renin-Activatable 2 quenched 675/693 43,000 g/mol Detection of kidney renin changes in
hypertension
AngioSense 680 Vascular Agent 1 680/700 250,000 g/mol Vascular leak in angiogenesis & edema
GastroSense 750 Oral Agent 1 750/770 40,000 g/mol Gastric emptying, gastrointestinal contrast
IntegriSense 750 Integrin Antagonist 1 755/775 1280 g/mol avb3 upregulation in disease
AngioSPARK 750 Nanoparticle Multiple 750/775 20–50 nm Vascularity, vascular leak
doi:10.1371/journal.pone.0020594.t001
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fluorescence in pmol using a variety of FR/NIR agents).
To determine the %ID/g in the different organs of living mice
without the contribution from circulating blood, pharmacokinetic
data was used to subtract blood levels from each organ at each
time point. This was done by assuming that all organ signal at the
first imaging time was due to fluorescence within the blood vessels
of the organ as depicted in Figure 1. For agents in which
significant bladder signal was detected at the first imaging time
point (IntegriSense, AngioSense, and AngioSPARK), the %ID for
bladder signal was used to adjust the starting %ID for the blood.
For example, IntegriSense showed ,10% of the injected dose in
the bladder at the first imaging time, so blood levels were corrected
to start at 90%. This was deemed an appropriate correction
because bladder clearance will obviously affect blood levels.
Minimal loss by excretion was seen for agents at this time. Time
point by time point subtraction of the average PK curve
(normalized to the first imaging time) from the whole organ tissue
distribution curve effectively ‘‘zeroes’’ the organs at the start – a
time when there has not been significant extravasation into tissue -
and reveals the kinetics of extravasation into the organ tissue.
Standard organ weights were determined in previous studies using
mice of the same strain and size (brain 0.42 g, lungs 0.23 g, liver
1.0 g, intestines 1.22 g, heart 0.12 g, bladder 0.12 g, stomach
0.18 g, kidneys 0.15 g each). Tissue weight values per ROI were
adjusted for liver and lung regions to account for only partial
capture by the placed ROIs (liver 0.75 g, lungs 0.2 g).
Ex vivo tissue assessment of biodistribution
After animals were imaged in vivo, they were sacrificed by
carbon dioxide asphyxiation. The organs (brain, heart, lungs, liver,
spleen, kidneys, stomach, intestines, skin, blood, and bladder) were
removed post-mortem then imaged by fluorescence reflectance
imaging using FMT 2500’s planar imaging capability and frozen
at 280 C. For some animals, organs were also subjected to a
homogenization procedure. The organ tissues were thawed in the
dark, and then weighed. The appropriate volume of PBS (0.5 mL/
mg of tissue) was added to each tissue prior to homogenization to
an even consistency. Planar fluorescence reflectance imaging was
used to measure the fluorescence from serial dilutions of each
homogenate (10 uL/sample) to assure quantification was per-
formed within ranges of fluorophore concentration not subject to
intermolecular fluorescence quenching. Appropriate dilutions of
normal tissue homogenates were used to measure background
fluorescence which was subtracted from the final calculations.
Pharmacokinetics
CD-1 or nude mice were injected IV with a known amount of
fluorogenic agent. Terminal blood samples were collected by
cardiac puncture from each mouse at the appropriate time point
following carbon dioxide asphyxiation. A minimum of two mice
were sampled for each time point. Plasma was collected by
centrifugation and diluted 1:2 in DMSO to assure capture of
maximal fluorescent signal. Plasma fluorescence was measured
using a fluorescence plate reader (Molecular Devices, Sunnyvale,
CA). The data was normalized to a standard curved prepared with
known concentrations of the agent to quantify blood levels in ug/
ml, and results were converted to percent of injected dose. Mouse
inter-strain differences in pharmacokinetic profiles were well
within the range of variability seen within mouse strains.
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